First Pharma to Restore Sense of Smell? Inside the FLAVOR Trial Quest to Treat Postviral Olfactory Loss
In this interview, I’m talking with Rick Geoffrion, Founder, President, and CEO of Cyrano Therapeutics, about FLAVOR, a Phase...
Moe Alsumidaie
“Minutes, Not Days”: Site-Centric AI and Clinical Trial Experience
The coordinator stared at a 400-page EHR export, convinced the week was lost—until an AI pre-screen flagged 23 likely-eligible...
How Small Biotechs Navigate Clinical Trial Vendor Oversight
At SCOPE Europe 2025, a panel on vendor identification, selection, and management highlighted a pragmatic blueprint for small biopharma:...
Shining Light on Women’s Health: A New Non-Drug Vaginal Therapy
In this interview, I spoke with Dr. Melanie Santos, Chief Medical Officer at Cern Corporation, about a novel low...
The Human Cost of Fragmented Technology: A Conversation with Veeva’s Bree Burks
At the Veeva R&D and Quality Summit in Boston, we spoke with Bree Burks, Vice President of Strategy at...
Dye-Driven Precision: Targeting Chemo Directly to Tumors
Lyle Small leads a biotech startup pursuing a bold new approach: dye-drug conjugates that carry chemotherapy directly to cancer...
Why Correcting Trial Imaging Errors at Central Review Is Too Late—and Too Expensive
The patient drove two hours each way for the trial, which her oncologist and she believed was her best...
Northwell Christina Brennan on Future of Site-Sponsor Partnerships
At the Veeva R&D and Quality Summit in Boston, we interviewed Dr. Christina Brennan, Senior Vice President of Clinical...
FDA’s National Priority Voucher Program Is Just a Modular PMA Rebrand, With Risks
In June 2025, FDA announced its new Commissioner’s National Priority Voucher (CNPV) program, a headline-grabbing reform that promises to...
AI’s Transformative Role in Colorectal Cancer Screening
In the dynamic field of gastroenterology, AI is revolutionizing clinical practices, particularly in colorectal cancer screening. Dror Zur, CEO...